Disc Medicine Inc. has announced the appointment of Nadim Ahmed to its Board of Directors. Ahmed, currently the President and CEO of Cullinan Therapeutics, brings over twenty-five years of experience in development and commercialization roles in the biopharmaceutical industry. His expertise in hematological diseases is expected to support Disc Medicine's efforts as it advances its hematology pipeline and prepares for the commercialization of bitopertin in EPP.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9493644-en) on July 14, 2025, and is solely responsible for the information contained therein.